ARQT: Total Zoryve TRx ~23.2K, Including Foam Zoryve TRx at ~11.8K and 0.15% Cream at ~5.0K for WE May 15, 2026

Research evidence excerpt

ARQT: Total Zoryve TRx ~23.2K, Including Foam Zoryve TRx at ~11.8K and 0.15% Cream at ~5.0K for WE May 15, 2026

rket or industry data and to compile company-specific information

to facilitate the recipient's preliminary review. In providing this research, we assume that any information obtained from public sources, data suppliers

(including AI systems) and other third parties is reasonable and reliable but acknowledge that any such information (including AI content) could contain

errors, inconsistencies, bias or outdated or irrelevant information. We seek to update our research as appropriate, but various regulations may prevent

us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as

appropriate in the research analyst's judgement. Guggenheim Securities conducts a full-service, integrated investment banking and brokerage business.

Guggenheim Securities is a member of SIPC (http://www.sipc.org). Guggenheim Securities' salespeople, traders, and other professionals may provide oral

or written market commentary or trading strategies to Guggenheim Securities' clients and our employees trading for our own account that reflect opinions

that are contrary to the opinions expressed in this research. Guggenheim and certain of our affiliates conduct an investment management business, trade

for their own accounts, and may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as

principal in, and buy or sell, the securities or derivatives, if any, referred to in this research.